

# Digital Data Flow

*Last Updated: 13th June 2023*

WITH STANDARDS – UNLOCK THE POWER OF DATA

This initiative aims to move the drug development process from a current state of manual, study start-up asset creation (i.e. Case Report Forms, Procedure Manuals, Statistical Analysis Plans, and Schedule of Activities) to a future state of fully automated, dynamic, study start-up readiness via an open-sourced, vendor-agnostic technical solution that will reduce cycle times and improve data quality for sponsors, third-party providers, sites and regulators.

## Links

- Transcelerate Digital Data Flow page
  - <https://www.transceleratebiopharmainc.com/initiatives/digital-data-flow/>
- CDISC DDF Page
  - <https://www.cdisc.org/ddf>
- CDISC Github
  - <https://github.com/cdisc-org/DDF-RA>

## Main Elements

- Reference Architecture (CDISC)
  - Unified Study Definitions Model (USDM)
  - Controlled Terminology (CT)
  - Application Programming Interface (API)
  - Implementation Guide (IG)
- Reference Implementation (Accenture), the Study Definitions Repository (SDR)



**2022**  
US  
INTERCHANGE  
26-27 OCTOBER | AUSTIN



**CDISC's Activities on DDF, Benefits for the Community, and Looking Ahead**

Presented by D Iberson-Hurst  
Partner d4k & CDISC DDF Product Owner

## Project Background (see slide deck above)


- Phase 1 -> USDM V1
- Phase 2 -> USDM V2
- **At GGG Approval Stage**
- **To Be Published July 2023**

## MIRO Board Status

- Used for technical run throughs
- Staging zone for Implementation Guide content
- **Status: Informational. Updated regularly**

# Phase One and Two

## CDISC DDF Phase One v Two



### CDISC DDF Phase One

July, 2021 – July 2022

- Unified Study Definitions Model (USDM) Class Diagram**  
The UML class diagram (normative) as well as SQL Data Dictionary, Entity Relationship Diagram and example JSON output (informative)
  - Application Programming Interface (API) Specification**  
The API definition (normative) in JSON and HTML forms
  - CDISC Controlled Terminology**  
The controlled terminology (normative) developed for the project. Provided in an Excel format so as to be easily searched and filtered.
  - Reference Architecture Conformance Tests**  
Provided by the functionality provided by tools such as SwaggerHub and Postman
  - Essential Users Stories**  
The User Stories, PDF document
  - Architecture Principles**  
The architectural principles developed by the project, PDF Document
  - Supporting Materials**  
A set of informational materials in PDF format to help understand the deliverables being reviewed, PDF documents or references.
- cdisc V1.0 Provisional <https://www.cdisc.org/ddf>


### Phase One & Two

- Small slide deck re Phase One and Two

### Changes Between Phase One and Two

- Addition of timing within studies to schedule activities accurately
- Addition of Biomedical Concepts (BCs)
- Improvements to CT handling
- Additional attributes in some classes to support TCB CPT

# UML Model



- The normative Unified Study Definitions Model (USDMD)
- Available from Github
  - CDISC Github
    - <https://github.com/cdisc-org/DDF-RA/tree/main/Deliverables/UML>

# Controlled Terminology

	A	B	C	D	E	F	G	H	I
	Row #	Entity Name	Role	Logical Data Model Name	NCI C-code	CT Item Preferred Name	Synonym(s)	Definition	Has Value List
12		StudyProtocolVersion	Entity	StudyProtocolVersion	C93490	Study Protocol Version		A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. (BRIDG)	N
13		StudyProtocolVersion	Attribute	briefTitle	C132345	Brief Protocol Title	Abbreviated Protocol Title	The short descriptive name for the protocol.	N
14		StudyProtocolVersion	Attribute	officialTitle	C132346	Official Protocol Title		The formal descriptive name for the protocol.	N
15		StudyProtocolVersion	Attribute	publicTitle	C94105	Public Protocol Title		The descriptive name of the protocol that is intended for the lay public, written in easily understood language.	N
16		StudyProtocolVersion	Attribute	scientificTitle	C132350	Scientific Protocol Title		A more extensive descriptive name of the protocol that is intended for medical professionals, written using medical and scientific language.	N
17		StudyProtocolVersion	Attribute	protocolVersion	C93490	Study Protocol Version		A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. (BRIDG)	N
18		StudyProtocolVersion	Attribute	protocolAmendment	C132347	Study Protocol Amendment		A written description of a change(s) to, or formal clarification of, a protocol. (ICH E6)	N
19		StudyProtocolVersion	Attribute	protocolEffectiveDate	C188817	Study Protocol Amendment Effective Date		The date and time specifying when the protocol amendment takes effect or becomes operative.	N
20		StudyProtocolVersion	Attribute	protocolStatus	C188818	Protocol Status		A condition of the protocol at a point in time with respect to its state of readiness for implementation.	Y (C188723)

## CT

- Provides a list of all classes and attributes
- Provides a definition
- Provides CT references
- Available from Github
- IG now has a UML and CT "merge" summary

## Links

- CDISC Github
  - <https://github.com/cdisc-org/DDF-RA/tree/main/Deliverables/CT>



# API

## Simple API for DDF

1.7 Provisional (0.31) OAS3

/openapi.json

A simple TransCelerate Digital Data Flow (DDF) Study Definitions Repository API.

Production

Routes that form the production specification.

^

POST

/v1/studyDefinitions

Create a study

▼

GET

/v1/studyDefinitions/{uuid}

Return a study

▼

PUT

/v1/studyDefinitions/{uuid}

Update a study

▼

GET

/v1/studyDefinitions/{uuid}/history

Returns the study history

▼

GET

/v1/studyDesigns

Study designs for a study

▼

## API

- OpenAPI specification
- Bulk API
- Available from Github

## Links

- CDISC Github
  - <https://github.com/cdisc-org/DDF-RA/tree/main/Deliverables/API>

# Implementation Guide

## Implementation Guide

- Note that the IG is version 2
- There was no IG with version 1 of the USDM
- Available from Github

## Links

- CDISC Github
  - <https://github.com/cdisc-org/DDF-RA/tree/main/Deliverables/IG>



## Unified Study Definitions Model Implementation Guide (USDM-IG)

### Version 2.0 (Draft for Internal Review)

Prepared by the  
DDF Team

#### Notes to Readers

- This is the draft version 2.0 of the Unified Study Definitions Model Implementation Guide (USDM-IG v2.0). It is intended for Internal Review only and is not a final version.


#### Revision History

Date	Version
2023-03-08	2.0 Draft for Internal Review

© 2023 Clinical Data Interchange Standards Consortium, Inc. All rights reserved.

# Overview

DDF Model  
12th April 2022  
Phase 2 Sprint 11, End of internal review, pre public review.  
For information Only




## Main Areas

- Study
  - Protocol Version
  - Study Identifiers
- Study Design
  - Arms, Epochs ...
  - Study Timing
  - Biomedical Concepts
  - Study Populations
  - Study Objectives & Endpoints
  - Study Estimands
  - Interventions
  - Indications
- Utility
  - CT References

## "Green Blob" Diagram

- **Not Normative**
- Informative view of the model
- Used to discuss ideas before putting into normative UML
- Used as a cross-check of normative deliverables at end of sprints





# AliasCode and Code

## AliasCode and Code

- Code is a standard code reference
  - CDISC CT
  - All other CT
- AliasCode is a mechanism to align a CDISC Code with codes from other CT
  - One standard (CDISC) code
  - Many alternatives

```
{
  "aliasCodeId": "id_123",
  "standardCode": {
    "codeId": "code_29",
    "code": "C25299",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Diastolic Blood Pressure"
  },
  "standardCodeAliases": [
    {
      "codeId": "code_30",
      "code": "8462-4",
      "codeSystem": "http://loinc.org/",
      "codeSystemVersion": "2022-03-25",
      "decode": "Diastolic Blood Pressure"
    },
    {
      "codeId": "code_31",
      "code": "271650006",
      "codeSystem": "SNOMED-CT",
      "codeSystemVersion": "2003",
      "decode": "Diastolic Blood Pressure"
    },
    {
      "codeId": "code_32",
      "code": "4154790",
      "codeSystem": "OHSDI",
      "codeSystemVersion": "",
      "decode": "Diastolic Blood Pressure"
    }
  ]
}
```





# Study

```

{
  "studyId": "<UUID HERE>",
  "studyTitle": "Small Simple Test Study (SSTS)",
  "studyVersion": "1",
  "studyType": {
    "codeId": "code_11",
    "code": "C98388",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Interventional Study"
  },
  "studyPhase": {
    "codeId": "code_10",
    "code": "C49686",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Phase IIa Trial"
  },
  "businessTherapeuticAreas": [
    {
      "codeId": "code_34",
      "code": "12345",
      "codeSystem": "Sponsor",
      "codeSystemVersion": "2022",
      "decode": "Business Unit A"
    }
  ],
  "studyIdentifiers": [],
  "studyProtocolVersions": [],
  "studyDesigns": [],
  "studyRationale": "Demonstration"
  "studyAcronym": "SSTS"
}


```

## Study

- Root of the whole model
- One study links to many study designs
- Study also links to
  - identifiers
  - protocol versions

## Instance Identifiers

- Study has a UUID (allocated by the SDR)
- All other objects have internal ids that should be unique across the study, used for cross-references
- See **red** in example




## Business Therapeutic Area

- Sponsor requested. More for downstream processes
- Not the same as StudyDesign therapeuticAreas attribute

## One Study, Many Study Designs


- USDM allows for many study designs within a single study
- This accommodates master, umbrella studies etc.





# Study Identifiers

## Study Identifiers

- Multiple identifiers permitted, various types
  - Sponsor
  - Registry
  - Regulatory Authority
- Should have a Sponsor Id
- Should only have one Sponsor Id
- Note the country code (ISO 3166-1)



```
{
  "studyIdentifierId": "study_identifier_id_3",
  "studyIdentifier": "ACME-5678",
  "studyIdentifierScope": {
    "organizationId": "organization_1",
    "organisationIdentifierScheme": "DUNS",
    "organisationIdentifier": "123456789",
    "organisationName": "ACME Pharma",
    "organisationType": {
      "codeId": "code_13",
      "code": "C70793",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "2022-03-25",
      "decode": "Clinical Study Sponsor"
    }
  },
  "organizationLegalAddress": {
    "text": "123",
    "line": "fake street",
    "city": "some town",
    "district": "district 19",
    "state": "TX",
    "postalCode": "12345",
    "country": {
      "codeId": "code_15",
      "code": "USA",
      "codeSystem": "ISO 3166 1 alpha3",
      "codeSystemVersion": "2020-08",
      "decode": "United States of America"
    }
  }
}
```




# Protocol Version


## Protocol

- Links the Study to the protocol version
- With DDF the existing protocol "document", e.g. MS Word, has been split into
  - a document
  - an electronic design (DDF USDM)
- Need to link which design is valid with which version of the document

## Protocol and Study Versions



```
"studyProtocolVersions": [
{
  "briefTitle": "COVACTA",
  "officialTitle": "A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",
  "publicTitle": "",
  "scientificTitle": "",
  "protocolVersion": "3",
  "protocolAmendment": null,
  "protocolEffectiveDate": "2020-06-11",
  "protocolStatus": {
    "code": "C85255",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Draft"
  }
}
]
```




# Study Design

## Study Design

- Root of a single design
- Links all the pieces

## Therapeutic Areas


Dictionary / Terminology Name	URL
EUROACT	<a href="https://eudract.ema.europa.eu/docs/technical/EUDRACT_Eutet_Pick_Lists_and_coded_values_v1.0.xls">https://eudract.ema.europa.eu/docs/technical/EUDRACT_Eutet_Pick_Lists_and_coded_values_v1.0.xls</a>
ICD-10	<a href="https://www.icd10data.com/ICD10CM/Codes">https://www.icd10data.com/ICD10CM/Codes</a>
MEDORA	<a href="https://www.meddra.org/">https://www.meddra.org/</a>
MeSH	<a href="https://www.ncbi.nlm.nih.gov/mesh/">https://www.ncbi.nlm.nih.gov/mesh/</a>
NCI Thesaurus	<a href="https://ncit.nci.nih.gov/ncitbrowser/">https://ncit.nci.nih.gov/ncitbrowser/</a>
SNOMEDCT	<a href="https://www.nlm.nih.gov/healthit/snomedct/index.html">https://www.nlm.nih.gov/healthit/snomedct/index.html</a>
US FDA	<a href="https://www.fda.gov/drugs/development-resources/spectrum-diseasesconditions">https://www.fda.gov/drugs/development-resources/spectrum-diseasesconditions</a>




```
{
  "studyDesignId": "study_design_1",
  "studyDesignName": "Study Design",
  "studyDesignDescription": "foobar",
  "trialIntentTypes": [
    {
      "codeId": "code_24",
      "code": "C15714",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "2022-03-25",
      "decode": "Basic Research"
    }
  ],
  "trialType": [
    {
      "codeId": "code_25",
      "code": "C158288",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "2022-03-25",
      "decode": "Biosimilarity Study"
    },
    {
      "codeId": "code_26",
      "code": "C49666",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "2022-03-25",
      "decode": "Efficacy Study"
    }
  ],
  "interventionModel": {
    "codeId": "code_27",
    "code": "C82639",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Parallel Study"
  },
  ... >>>
}
```

```
{
  <<< ...
  "studyCells": [],
  "studyIndications": [],
  "studyInvestigationalInterventions": [],
  "studyStudyDesignPopulations": [],
  "studyObjectives": [],
  "studyWorkflows": [],
  "therapeuticAreas": [
    {
      "codeId": "code_28",
      "code": "123456789",
      "codeSystem": "SNOMED",
      "codeSystemVersion": "2022",
      "decode": "Something"
    }
  ],
  "studyEstimands": [],
  "encounters": [],
  "activities": [],
  "studyDesignRationale": "",
  "studyDesignBlindingScheme": null,
  "biomedicalConcepts": [],
  "bcCategories": [],
  "bcSurrogates": []
}
```







# Study Populations




```
"studyStudyDesignPopulations": [
{
  "studyDesignPopulationId": "population_1",
  "populationDescription": "Population 1",
  "plannedNumberOfParticipants": 100,
  "plannedMaximumAgeOfParticipants": "80 years",
  "plannedMinimumAgeOfParticipants": "18 years",
  "plannedSexOfParticipants": []
}
]
```




# Study Objectives and Endpoints




```
"studyObjectives": [
{
  "objectiveDesc": "Evaluate sensitivity index from baseline to end of study (16 weeks)",
  "objectiveLevel": {
    "code": "C85826",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Trial Primary Objective"
  },
  "objectiveEndpoints": [
    {
      "endpointDesc": "Survival rate after cycle 8 of treatment",
      "endpointPurposeDesc": "EFFICACY",
      "endpointLevel": {
        "code": "C94496",
        "codeSystem": "http://www.cdisc.org",
        "codeSystemVersion": "2022-03-25",
        "decode": "Primary Endpoint"
      }
    }
  ]
}
]
```




# Interventions



```
"studyInvestigationalInterventions": [
  {
    "codes": [
      {
        "code": "XX031ZA",
        "codeSystem": "ATC",
        "codeSystemVersion": "2021",
        "decode": "SubstX"
      }
    ],
    "interventionDesc": "Treatment with substX"
  }
]
```




# Indications




```

"studyIndications": [
  {
    "codes": [
      {
        "code": "E11",
        "codeSystem": "ICD-10-CM",
        "codeSystemVersion": "10",
        "decode": "Type 2 diabetes mellitus"
      },
      {
        "code": "44054006",
        "codeSystem": "SNOMED",
        "codeSystemVersion": "2022",
        "decode": "Diabetes mellitus type 2 (disorder)"
      }
    ],
    "indicationDesc": "Diabetes Type II"
  },
  {
    "codes": [
      {
        "code": "E10",
        "codeSystem": "ICD-10-CM",
        "codeSystemVersion": "10",
        "decode": "Type 1 diabetes mellitus"
      },
      {
        "code": "44635009",
        "codeSystem": "SNOMED",
        "codeSystemVersion": "2022",
        "decode": "Diabetes mellitus type 1 (disorder)"
      }
    ],
    "indicationDesc": "Diabetes Type I"
  }
]

```




# Study Estimands



```

"studyEstimands": [
  {
    "estimandId": "Estimand_1",
    "summaryMeasure": "Survival of all patients",
    "analysisPopulation": {
      "analysisPopulationId": "AnalysisPopulation_1",
      "populationDescription": "ITT"
    },
    "treatment": "InvestigationalIntervention_2",
    "variableOfInterest": "Endpoint_1",
    "intercurrentEvents": [
      {
        "intercurrentEventId": "IntercurrentEvent_1",
        "intercurrentEventName": "termination",
        "intercurrentEventDescription": "IC Event Description",
        "intercurrentEventStrategy": "Patients with out of range lab values before dosing will be excluded"
      }
    ]
  }
]


```



# Arms, Epoch etc

## High Level Study Design

- Arms & Epochs
- Cells
- Elements
- Encounters (Visits)
- Entry and Exit Rules
- Can be used as a start of SDTM Trial Design Domain population
- Also T domains can be imported to build a study design "framework"



```

{
  "studyCellId": "study_cell_1",
  "studyArm": {
    "studyArmId": "study_arm_id_1",
    "studyArmName": "Placebo",
    "studyArmDescription": "The Placebo Arm",
    "studyArmType": {
      "codeId": "code_20",
      "code": "C174268",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "2022-03-25",
      "decode": "Placebo Control Arm"
    },
    "studyArmDataOriginDescription": "Captured subject data",
    "studyArmDataOriginType": {
      "codeId": "code_18",
      "code": "C6574y",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "1",
      "decode": "SUBJECT DATA"
    }
  },
  "studyEpoch": {
    "studyEpochId": "study_epoch_data_id_1",
    "studyEpochName": "Run In",
    "studyEpochDescription": "The run in",
    "studyEpochType": {
      "codeId": "code_21",
      "code": "C98779",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "2022-03-25",
      "decode": "Run-in Period"
    }
  },
  ...
}

```


# Trial Summary Domain

## Trial Summary (TS) Domain

- Initial mapping
- In the IG


Code	CDISC Submission Value	CDISC Synonym(s)	CDISC Definition	NCI Preferred Term	USDM Entity Name	USDM Role	USDM Item Name
C101302	THERAREA	Therapeutic Area	A knowledge field that focuses on research and development of specific treatments for diseases and pathologic findings, as well as prevention of conditions that negatively impact the health of an individual. (NCI)	Therapeutic Area	StudyDesign	Attribute	therapeuticAreas
C112038	INDIC	Trial Disease/Condition Indication; Trial Disease/Condition Indication Description	The textual representation of the condition, disease or disorder that the clinical trial is intended to investigate or address.	Trial Indication	Indication	Entity	Indication
C112038	INDIC	Trial Disease/Condition Indication; Trial Disease/Condition Indication Description	The textual representation of the condition, disease or disorder that the clinical trial is intended to investigate or address.	Trial Indication	Indication	Attribute	indicationDescription
C142175	STYPE	Study Type; Study Type Classification	The nature of the investigation for which study information is being collected. (After clinicaltrials.gov)	Study Type	Study	Attribute	studyType
C48281	TPHASE	Trial Phase; Trial Phase Classification	A step in the clinical research and development of a therapy from initial clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. A therapeutic intervention may be evaluated in two or more phases simultaneously in different trials, and some trials may overlap two different phases. [21 CFR section 312.21; After ICH Topic E8 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]	Trial Phase	Study	Attribute	studyPhase
C49652	TINDTP	Trial Intent Type	The planned purpose of the therapy, device, or agent under study in the clinical trial.	Clinical Study by Intent	StudyDesign	Attribute	trialIntentType
C49658	TBLIND	Study Blinding Design; Study Blinding Schema; Study Masking Design; Trial Blinding Design; Trial Blinding Schema; Trial Masking Design	The type of experimental design used to describe the level of awareness of the study subjects and/ or study personnel as it relates to the respective intervention(s) or assessments being observed, received or administered.	Trial Blinding Schema	StudyDesign	Attribute	studyDesignBlindingScheme
C49660	TTYPE	Trial Scope; Trial Type	The nature of the interventional study for which information is being collected.	Trial Type	StudyDesign	Attribute	trialType
C49692	PLANSUB	Anticipated Enrollment; Planned Enrollment; Planned Number of Subjects; Target Enrollment	The planned number of subjects to be entered in a clinical trial. (NCI)	Planned Subject Number	StudyDesignPopulation	Attribute	plannedNumberOfParticipants
C49693	AGEMIN	Planned Minimum Age of Subjects	The anticipated minimum age of the subjects to be entered in a clinical trial. (NCI)	Planned Minimum Age of Subjects	StudyDesignPopulation	Attribute	plannedMinimumAgeOfParticipants
C49694	AGEMAX	Planned Maximum Age of Subjects	The anticipated maximum age of the subjects to be entered in a clinical trial. (NCI)	Planned Maximum Age of Subjects	StudyDesignPopulation	Attribute	plannedMaximumAgeOfParticipants
C49696	SEXPOP	Sex of Participants	The specific sex, either male, female, or mixed of the subject group being studied. (NCI)	Sex of Study Group	StudyDesignPopulation	Attribute	plannedSexOfParticipants
C49802	TITLE	Official Study Title; Study Title; Trial Title	The sponsor-defined name of the clinical study.	Trial Title	Study	Attribute	studyTitle
C98746	INTMODEL	Intervention Model	The general design of the strategy for assigning interventions to participants in a clinical study. (clinicaltrials.gov)	Intervention Model	StudyDesign	Attribute	interventionModel
C70793	SPONSOR	Clinical Study Sponsor; Sponsor; Study Sponsor	An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical study. [After ICH E6, WHO, 21 CFR 50.3 (e), and after IDMP]	Clinical Study Sponsor	Organization	Valid Value	Valid Value Set for Attribute organizationType
C85826	OBJPRIM	Study Primary Objective; Trial Primary Objective	A principle objective of the study.	Trial Primary Objective	Objective	Valid Value	Valid Value Set for AttributeobjectiveLevel
C85827	OBJSEC	Study Secondary Objective; Trial Secondary Objective	An auxiliary objective of the study.	Trial Secondary Objective	Objective	Valid Value	Valid Value Set for AttributeobjectiveLevel

# Activities, Encounters & "Glue"




## Linking Encounters with Activities

- Scheduled Activity Instance links encounters with Activities
  - Timing also provided by linking Scheduled Activity Instance to Timing
  - Activity links onto Procedures and BCs
- 
- Important piece is the Activity <-> "timing" <-> Encounter linkage






# Procedures




## Procedures

- Linked from activities with multiple procedures per activity
- Name and description added during internal review
- Can be conditional with condition expressed as text

```
{
  "procedureId": "Procedure_2",
  "procedureType": "XXX",
  "procedureName": "Test9",
  "procedureDescription": "Test Nine",
  "procedureCode": {
    "codeId": "Code_7",
    "code": "12345679",
    "codeSystem": "SNOMED",
    "codeSystemVersion": "January 31, 2018",
    "decode": "Test"
  },
  "procedureIsConditional": true,
  "procedureIsConditionalReason": "Only do it they have man flu"
}
```




# Encounters




## Encounters

- Definition of an encounter
- Cross referenced from Epochs
- References timing to detail the encounter window
- Note encounter type, currently only value is "Visit"

```
{
  "encounterId": "Encounter_1",
  "encounterName": "Screening",
  "encounterDescription": "Screening encounter",
  "previousEncounterId": null,
  "nextEncounterId": "Encounter_2",
  "encounterType": {
    "codeId": "Code_13",
    "code": "C25716",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-12-16",
    "decode": "Visit"
  },
  "encounterEnvironmentalSetting": {
    "codeId": "Code_14",
    "code": "C51282",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-12-16",
    "decode": "Clinic"
  },
  "encounterContactModes": [],
  "transitionStartRule": {
    "transitionRuleId": "TransitionRule_1",
    "transitionRuleDescription": "Subject identified"
  },
  "transitionEndRule": {
    "transitionRuleId": "TransitionRule_2",
    "transitionRuleDescription": "IEs passed"
  },
  "encounterScheduledAtTimingId": null
}
```



# Biomedical Concepts I



## DDF, USDM and Biomedical Concepts

Dave Ibersen-Hurst  
 15<sup>th</sup> December 2022





## Slide Deck

- Sets the scene for BCs
- Used several times to provide the background around BCs

# Biomedical Concepts II

## View of an CDISC API Instance

- Image is a little old now but useful if you are not familiar with the idea of BCs
- Note
  - Central note and the multiple "data concept" or "property" nodes
  - Code responses or definition, e.g.
    - identification is a single code
    - units has multiple codes
- USDM BCs have three levels, see model below



# Biomedical Concepts III


## Github Example

[Full JSON Examples](#), see example

```
---
BiomedicalConcept:
  bcName: Diastolic Blood Pressure
  bcConceptId:
    standardCode:
      code: C25299
      codeSystem: http://www.cdisc.org
      codeSystemVersion: "2022-03-25"
      decode: Diastolic Blood Pressure
    standardCodeAliases:
      -
        code: 8462-4
        codeSystem: http://loinc.org/
        codeSystemVersion: "2022-03-25"
        decode: Diastolic Blood Pressure
      -
        code: 271650006
        codeSystem: SNOMED-CT
        codeSystemVersion: "2003"
        decode: Diastolic blood pressure
      -
        code: 4154790
        codeSystem: OHSDI
        codeSystemVersion:
        decode: Diastolic blood pressure
    ...
  bcSynonyms:
    - DIABP
    - DIA BP
    - Blood pressure diastolic
    ...
  bcProperties:
    -
      ...
```

bcProperties:


```
-
  bcPropertyName: Vital Signs Result
  bcPropertyEnabled: true
  bcPropertyRequired: true
  bcPropertyDataType: integer
  bcPropertyConceptId:
    code: C173522
    codeSystem: http://www.cdisc.org
    codeSystemVersion: "2022-03-25"
    decode: Vital Signs Result
  bcPropertyResponseCodes: []
-
  bcPropertyName: Unit of Pressure
  bcPropertyEnabled: true
  bcPropertyRequired: true
  bcPropertyDataType: string
  bcPropertyConceptId:
    code: C49669
    codeSystem: http://www.cdisc.org
    codeSystemVersion: "2022-03-25"
    decode: Unit of Pressure
  bcPropertyResponseCodes:
    -
      responseCodeEnabled: true
      code:
        code: C49670
        codeSystem: http://www.cdisc.org
        codeSystemVersion: "2022-03-25"
        decode: mmHg
    -
      responseCodeEnabled: true
      code:
        code: C42547
        codeSystem: http://www.cdisc.org
        codeSystemVersion: "2022-03-25"
        decode: Pascal
```



# Study Design and Timing

## "Timepoints"

- "Timepoints" was a label given to this area on the DDF project just for easy identification of an area of work.
- It is all about study timing



## Slide Deck

- Outlines requirements (slides 7-26)
  - Complex timing
  - Branching
  - Cycles
- Slides 28-44 provide "instance" examples to explain the ideas
- Things have moved on since the slide set was written
  - For example, class naming has changed
  - Still useful for overall concept

## Basics

- Based upon a “timeline” that uses
  - Entry and Exit
  - Conditions
  - Activity Instances
  - Condition Instances
  - Timing
- Activity Instances are linked by Timing information to position the instances in the timeline
- Linked to encounters, activities as per the current USDM
- Timelines can be referenced and reused

See JSON examples  
[main branch](#)  
[v14.2 branch](#)


v14.2 Branch  
is "work in  
progress",  
fixing issues

A **ScheduledActivityInstance** Example.  
Colour coding to match diagram

```

{
  ...
  {
    "scheduledInstanceId": "ScheduledActivityInstance_1",
    "scheduledInstanceType": "ACTIVITY",
    "scheduleTimelineExitId": null,
    "scheduledInstanceTimings": [...],
    "scheduledInstanceTimelineId": null,
    "defaultConditionId": "ScheduledActivityInstance_2",
    "epochId": "StudyEpoch_1",
    "activityIds": [ ... ],
    "scheduledActivityInstanceEncounterId": "Encounter_1"
  },
  ...
}

```







# Timing

## Basics

- Two types of relationship
  - Anchor - A fixed point
  - Before or After - A relative point
- Window can be defined
- Descriptive and coded timing values
- Coded values are ISO8601 Durations

```
{
  "timingId": "Timing_3",
  "timingType": {
    "codeId": "Code_41",
    "code": "C99901x1",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-12-16",
    "decode": "After"
  },
  "timingValue": "P3D",
  "timingDescription": "3 Days",
  "timingRelativeToFrom": {
    "codeId": "Code_44",
    "code": "C99900x1",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-12-16",
    "decode": "Start to Start"
  },
  "relativeFromScheduledInstanceId": "ScheduledActivityInstance_3",
  "relativeToScheduledInstanceId": "ScheduledActivityInstance_2",
  "timingWindowLower": "PT12H",
  "timingWindowUpper": "PT12H",
  "timingWindow": "12..12 Hours"
}
```

Note that the C codes yet to be allocated so "C99901xN" are example codes. Will be allocated for September 2023 CT Release






# Branching

## Basics

- Uses the Decision Instance
- Defined as a switch
- A set of (condition, destination) pairs
- A default link (if no condition is met)



## Github Example

See JSON examples  
[main branch](#)  
[v14.2 branch](#)




# Unscheduled

## Basics

- Each potential unscheduled event handled as a timeline
- One main path
- Several child paths for unscheduled events
- A condition for each
- As many instances and timing as needed
- Linked to activities, encounters as needed
- Some instances need not be linked to encounters

### Examples Being Worked On


Example needed, similar to profile but an example will be provided



# Cycles

## Basics

- One mechanism for implementing cycles
- Other patterns could be implemented




# USDM Examples I

## Test Utility

- Developing a test utility:
  - Multi-sheet Excel file containing a full USDM definition (bar one or two pieces)
  - Intended to build the full USDM JSON
  - Also builds a visualisation
- Will be available as a python package

## Github Examples

See JSON examples  
[main branch](#)  
[v14.2 branch](#)




## Note

- No BC category example as yet

Current Examples


- A Roche Study
- CDISC Pilot Study
- Eli Lilly Study
- Others
  - Simple example
  - Cycle example
  - Profile example

			Epoch	Screening	Baseline	Treatment	Follow-Up
			Cycle	-	-	-	-
			First Cycle Start	-	-	-	-
			Cycle Period	-	-	-	-
			Cycle End Rule	-	-	-	-
			Timing	N: 0..2 Days	N: Pre Dose	A: 15 min	P: +24 Hours
			Visit Label	Screening	Baseline	0.1 Hours	Day 24
			Visit Window		0..4 Hours		Day 35
Parent Activity	Child Activity	BC/Profile					
-	Demographics	BC:Age, BC:Sex, BC:Race		X	-	-	-
-	Something Else	-		X	X	X	X



```
1 {
2   "studyId": null,
3   "studyTitle": "Simple Test 1",
4   "studyVersion": "1",
5   "studyType": {
6     "codeId": "Code_1",
7     "code": "C98388",
8     "codeSystem": "http://www.cdisc.org",
9     "codeSystemVersion": "2022-12-16",
10    "decode": "Interventional Study"
11  },
12  "studyPhase": {
13    "aliasCodeId": "AliasCode_1",
14    "standardCode": {
15      "codeId": "Code_2",
16      "code": "C15602",
17      "codeSystem": "http://www.cdisc.org",
18      "codeSystemVersion": "2022-12-16",
19      "decode": "Phase III Trial"
20    },
21    "standardCodeAliases": []
22  },
23  "businessTherapeuticAreas": [{}],
24  "studyIdentifiers": [{}],
25  "studyProtocolVersions": [{}],
26  "studyDesigns": [{}],
27  "studyRationale": "A simple test",
28  "studyAcronym": "SIMPLE"
29 }
```

# USDM Examples II



## Web Version

Online conversion [tool here](#).

## USDM Excel to JSON Utility

## Excel File List

A list of files held within the system for which a converted USDM JSON file can be downloaded.

## File List

Roche Phase 3 NCT04320615.xlsx, dated 2023-04-14		
cycles_1.xlsx, dated 2023-04-14		
simple_3.xlsx, dated 2023-04-14		

Upload New Excel File

[CLICK TO UPLOAD NEW FILE](#)

### Online Utility

- Saves installing any software
- Will upload Excel file and return JSON equivalent
- No login as yet but will be added

## Visualise Examples

## Online Utility

Useful JSON tool, [JSON Crack Editor](#)

- Useful visualisation
- Does NOT do cross references

**USDM Excel Sheet Formats & Links Infographic**  
1st May 2023

Details of the package can be found at <https://github.com/datasets-knowledge/usdm>. Details for using the package and the sheet formats are detailed within the readme file within the repository.

All sheets are required to be present within the workbook and sheets are read automatically by the package. The diagrams are here to show the cross sheet references/links to aid in the assembly of study designs

studyDesignArms Sheet

	A	B	C	D	E
1	studyArmName	studyArmDescription	studyArmType	studyArmDataOriginDescription	studyArmDataOriginType
2	Active	Active Substance	Active Comparator Arm	Data collected from subjects	Data Generated Within Study
3	Placebo	Placebo	Placebo Comparator Arm	Data collected from subjects	Data Generated Within Study

	A	B	C	D	E	studyIdentifiers Sheet
1	organizationalIdentifierScheme	organizationalIdentifier	organizationName	organizationType	studyIdentifier	organizationAddress
2	USGVS	CT-GOV	ClinicalTrials.gov	Study Registry	NCT02181618	line1(city country state postal code, state, country)
3	USGVS	123456789	ACME Pharma	Clinical Study Sponsor	AP1234	Somewhere (in a City) in a District (in a Big state) 12345 (PMA)

	A	B	C	D	E
1	populationDescription	plannedNumberOfParticipants	plannedMinimumAgeOfParticipants	plannedMaximumAgeOfParticipants	plannedSexOfParticipants
2	Pop 1	100 18 years	40 years		BOTH
3	Pop 2	20 18 years	60 years		M
4	Pop 3	20 18 years	30 years		F

[illegible]

A	B	C	D
1	srcf	type	description
2	IND	IND	An indication
3	INT2	INT	An intervention
4	IND	IND	An indication
5	INT2	INT	An intervention

Timeline name: Sheet									
	A	B	C	D	E	F	G	H	I
1	Name: Main Timeline		Event		Screening	Baseline	Treatment	Follow Up	
2	Description: This is the main timeline for the study design.		First Cycle Start						
3	Causal: Independent variable identified		Cycle Period						
4			Cycle End Date						
5			Timing		At 0	At Pre-Dose	At	P+24 hours	P+7 days
6			Exposure start						
7			Window		0-4 Hours	0-4 hours			-3 days
8	Parent Activity	Child Activity	BC/Procedure/Timeline						
9		- Demographics		BC, SC, BC, BC, BC, BC, Body Weight	X	X	X	X	X
10		- Something Else							

	A	B	C	D	E	F	G	H
1	trial	encounterName	encounterDescription	encounterType	encounterEnvironmentSetting	encounterContactModes	transitionable	transitionable
2		Screening	Screening encounter	Visit	Clinic	In Person	Subject identified	ES passed
3	12	Baseline	Baseline encounter	Visit	Clinic	In Person		
4	13	15 min	Post date	Visit	Clinic	In Person	Randomized	
5	14	Day 24	2 week visit	Visit	Clinic	In Person		
6	15	Day 35	3 week visit	Visit	HOME	TELEPHONE CALL		

studyDesignProcedures Sheet			
	E	F	G
question	procedureCode	proceduresConditional	proceduresConditionalReason
	SNOMED: 12345678-Test		
	SNOMED: 12345679-Test	Y	Only do it they have man flu

	A	B	C	D	E
	study	studyElementName	studyElementDescription	transitionStartDate	transitionEndDate
1	011	Screening	Screening Element	Study Start	Screened
2	012	Baseline	Baseline Element	Screened	Randomized
3	013	Treatment 1	Treatment Element 1	Randomized	Completed treatment 1
4	014	Treatment 2	Treatment Element 2	Completed	Lost to Follow Up
5	015	Treatment 2	Treatment Element 2	Randomized	Completed treatment 2

	A	B	C	D	E	F	G
	objectiveKey	objectiveDescription	objectiveKey	endpointKey	endpointDescription	endpointKey	endpointDescription
1	OBJ1	The primary efficacy objective for this study is to compare the efficacy of T2 compared with placebo in combination with SOC for the treatment of severe COVID-19 pneumonia	END1	Time to clinical improvement (TCI) defined as a National Early Warning Score 2 (NEWS2) of $\leq 4$ maintained for 24 hours	Primary Endpoint		
2	OBJ2	The secondary efficacy objective for this study is to measure the efficacy of T2 compared with placebo in combination with SOC for the treatment of severe COVID-19 pneumonia	END2	Time to clinical improvement (TCI) defined as a National Early Warning Score 2 (NEWS2) of $\leq 4$ maintained for 24 hours	Secondary Endpoint		
3			END3	Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status	Secondary Endpoint		
4			END4	Incidence of mechanical ventilation	Secondary Endpoint		
5			END5	Incidence of intubation free days by Day 28	Secondary Endpoint		
6			END6	Incidence of intubation free days with EOI by day 28	Secondary Endpoint		
7			END7	Duration of ICU stay	Secondary Endpoint		
8			END8	Time to clinical failure, defined as the time to death, mechanical ventilation, ICU admission, or withdrawal without return to baseline	Secondary Endpoint		
9			END9	Time to clinical failure, defined as the time to death, mechanical ventilation, ICU admission, or withdrawal without return to baseline	Secondary Endpoint		
10			END10	Mortality rate by Days 1, 14, 21, 28, and 60	Secondary Endpoint		
11			END11	"Time to hospital discharge" "Time for discharge" (as evaluated by normal body temperature and respiratory rate, and stable oxygen saturation on $\text{FiO}_2 \leq 0.3$ supplemental oxygen)	Secondary Endpoint		
12			END12	"Time to recovery, defined as discharged" "Time for discharge" (as evaluated by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or $\text{FiO}_2 \leq 0.3$ supplemental oxygen) OR, a non-ICU hospital ward for "Time for hospital ward" (as requiring supplemental oxygen)	Secondary Endpoint		
13			END13	Duration of supplemental oxygen	Secondary Endpoint		

Download high resolution [version here](#)  
Further info will be added

# Conformance & Rules

Class	Attributes (Generic names)	Rules
StudyDesign, StudyEpoch, Encounter, ScheduleTimeline, Activity, Procedure, BiomedicalConceptSurrogate, BiomedicalConceptCategory	Name and Description attributes	Name should always be present but Description is optional
Activity, Procedure	Conditional and ConditionalReason	If Conditional is true then Reason must be present. If false then reason should be ignored
Timing	timingWindow, timingWindowLower, timingWindowUpper	If timing window present then Lower and Upper should be present
	From To	For anchor then To does not need to be set or could be set the same as From
ScheduledInstance	defaultConditionId, scheduleTimelineExitId	Only one should be set. Generally default is set, but if Exit is set then no default.

Work In Progress  
Starting to think of the  
more complex, cross-field,  
"rules"

Look to implement as  
CORE rules

This will be part of Phase 3